The Patent Finder

Peptides and Compositions for Treatment of Joint Damage

Novartis AG

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 7 of these applications claim priority to application 61/775,400, filed Mar 8, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 9,745,358Peptides and Compositions for Treatment of Joint Damage
In force
 · High confidence
Novartis AGIn force
High confidence
US 10,239,927Peptides and Compositions for Treatment of Joint Damage
In force
 · High confidence
Novartis AGIn force
High confidence
US 10,328,126Peptides and Compositions for Treatment of Joint Damage
In force
 · High confidence
Novartis AGIn force
High confidence
US 10,533,042Peptides and Compositions for Treatment of Joint Damage
In force
 · High confidence
Novartis AGIn force
High confidence
US 11,179,442Peptides and Compositions for Treatment of Joint Damage
In force
 · High confidence
Novartis AGIn force
High confidence
US 9,301,971Peptides and Compositions for Treatment of Joint Damage
In force
 · High confidence
Irm LLC.In force
High confidence
US 11,111,283Peptides and Compositions for Treatment of Joint Damage
In force
 · High confidence
Novartis AGIn force
High confidence
US 11,370,820Peptides and Compositions for Treatment of Joint Damage
In force
 · High confidence
Novartis AGIn force
High confidence
Application 17/453,960Peptides and Compositions for Treatment of Joint Damage
Abandoned
Abandoned Sep 9, 2023
Novartis AGAbandonedAbandoned Sep 9, 2023
Application 17/664,810Peptides and Compositions for Treatment of Joint Damage
Abandoned
Abandoned May 31, 2024
Novartis AGAbandonedAbandoned May 31, 2024
10 of 10 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
7 of these are in force and held by Novartis AG.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited